Search

Displaying results 881 - 890 of 4539 in total
  1. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates

  2. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is no longer available in the US market.

  3. Drug

    2-(aminomethyl)phenol

    go.drugbank.com/drugs/DB14855
    Investigational

    2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Older Adults).

  4. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

  5. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  6. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...

  7. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … FDA approved an expanded indication for Mavyret, making it the first and only direct-acting antiviral therapy approved for the treatment of both acute and chronic HCV in patients aged three years and older

  8. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    It is not approved for use in any country, but is currently in clinical trials in the United States.

  9. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    These cells are CD362 enriched umbilical cord-derived mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this … Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties.

  10. Drug

    Dirithromycin

    go.drugbank.com/drugs/DB00954
    Investigational

    Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.